Evidence map›Paper›PMID 41011239›Full record

ReviewPharmaceuticals (Basel, Switzerland)2025

Progress of ERK Pathway-Modulated Natural Products for Anti-Non-Small-Cell Lung Cancer Activity.

Lin Xing, Chi Zhang, Jieying Yuan, Kai Zhu, Helena Tomás, Ruilong Sheng, Xiuwei H Yang, Qidong Tu, Ruihua Guo

Abstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lin XingCollege of Food Science and Technology, Shanghai Ocean University, Shanghai 201306, China.
Chi ZhangCollege of Food Science and Technology, Shanghai Ocean University, Shanghai 201306, China.
Jieying YuanCollege of Food Science and Technology, Shanghai Ocean University, Shanghai 201306, China.
Kai ZhuCollege of Food Science and Technology, Shanghai Ocean University, Shanghai 201306, China.
Helena TomásCQM-Centro de Química da Madeira, Universidade da Madeira, Campus da Penteada, 9000-390 Funchal, Portugal.ORCID 0000-0002-7856-2041
Ruilong ShengCQM-Centro de Química da Madeira, Universidade da Madeira, Campus da Penteada, 9000-390 Funchal, Portugal.ORCID 0000-0002-3303-3832
Xiuwei H YangDepartment of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY 40506-0107, USA.ORCID 0000-0002-5591-6951
Qidong TuJiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science & Technology Normal University, Nanchang 330013, China.
Ruihua GuoCollege of Food Science and Technology, Shanghai Ocean University, Shanghai 201306, China.ORCID 0000-0001-8414-886X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent decades, there has been a significant increase in new lung cancer cases and deaths globally, especially in China, which hindered the extension of human life expectancy and severely threatened public health. Natural products are important and sustainable sources of new anticancer drug molecules, offering new bioactive molecules with various structures and biofunctions for new anticancer drug development, which accounted for 40% of all anticancer drugs. Natural-based compounds could inhibit cancer cell proliferation and migration through a variety of anticancer mechanisms by the modulation/regulation of multiple biotargets and cell signaling pathways. In this review, we summarized the anticancer activities of flavonoids, terpenoids, glycosides, alcohols, coumarins, saccharides, and other natural compounds that could modulate the ERK-related signaling pathway in non-small-cell lung cancer (NSCLC) cells. We further elucidated the mechanistic pathways of natural compound combinations and computationally predicted their molecular docking affinities with ERK1/ERK2 protein targets, as well as providing an outlook on current studies, with the expectation that natural compounds will play more significant roles in future antitumor chemotherapy regimens.

Indexed as

bioactive ingredientsERK signaling pathwaymolecular dockingnatural productsnon-small-cell lung cancer

Identifiers

PMID41011239
PMCPMC12472488

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.